疫苗接种是常规儿童和青少年预防保健的重要组成部分。我们试图确定当前肿瘤学提供者对儿童和青少年癌症患者和幸存者接种疫苗的做法、障碍和态度。我们于 2018 年 3 月至 10 月向美国九个机构的儿科肿瘤学家分发了一项一次性在线调查（N = 111，参与率68.8%）。调查内容包括32个项目，内容涉及疫苗接种实践、治疗后疫苗接种的障碍、肿瘤诊所疫苗接种的可用性、对疫苗指南的熟悉程度以及对疫苗接种责任的态度。描述性统计数据在 STATA 14.2 中进行计算。参与者中 54.0% 为女性，82.9% 为白人，其中 12.6% 专门从事骨髓移植。流感是治疗后最常见的恢复疫苗（7030%）。大约 50%-60% 熟悉免疫功能低下患者的疫苗指南。超过一半 (62.7%) 建议患者在化疗后 6 个月至 1 年内重新开始大多数免疫接种。提供者推荐疫苗接种的常见障碍包括没有患者之前的疫苗记录（56.8%）或缺乏时间确定需要哪些疫苗（32.4%）。在参与者中，66.7% 表示疫苗接种应由初级保健提供者管理，但需要肿瘤学家的指导。许多儿科肿瘤学家表示不熟悉针对免疫功能低下患者的疫苗指南，而且几乎所有人都报告在癌症治疗后支持患者接种疫苗方面存在障碍。我们的研究结果表明，需要进一步的研究和干预措施来帮助连接肿瘤护理和治疗后免疫接种的初级护理。© 2023。作者。

Vaccinations are a vital part of routine childhood and adolescent preventive care. We sought to identify current oncology provider practices, barriers, and attitudes towards vaccinating childhood and adolescent cancer patients and survivors.We conducted a one-time online survey distributed from March-October 2018 to pediatric oncologists at nine institutions across the United States (N = 111, 68.8% participation rate). The survey included 32 items about vaccination practices, barriers to post-treatment vaccination, availability of vaccinations in oncology clinic, familiarity with vaccine guidelines, and attitudes toward vaccination responsibilities. Descriptive statistics were calculated in STATA 14.2.Participants were 54.0% female and 82.9% white, with 12.6% specializing in Bone Marrow Transplants. Influenza was the most commonly resumed vaccine after treatment (7030%). About 50%-60% were familiar with vaccine guidelines for immunocompromised patients. More than half (62.7%) recommended that patients restart most immunizations 6 months to 1 year after chemotherapy. Common barriers to providers recommending vaccinations included not having previous vaccine records for patients (56.8%) or lacking time to ascertain which vaccines are needed (32.4%). Of participants, 66.7% stated that vaccination should be managed by primary care providers, but with guidance from oncologists.Many pediatric oncologists report being unfamiliar with vaccine guidelines for immunocompromised patients and almost all report barriers in supporting patients regarding vaccines after cancer treatment. Our findings show that further research and interventions are needed to help bridge oncology care and primary care regarding immunizations after treatment.© 2023. The Author(s).